Aadi Bioscience, Inc. (AADI) Tops Q3 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Aadi Bioscience Announces Financial Results for the Third Quarter of 2022 and Provides Corporate Update
November 9, 2022 8:01 AM ESTCompleted $72.5 million PIPE financing extending cash runway into 2025
PRECISION 1 trial on-track with preliminary data expected in the first half of 2023
24% revenue growth of FYARRO® (nab-sirolimus) over the second quarter 2022
Appointment of Neil Desai to Executive Chairman and transition of Brendan Delaney to CEO effective January 1, 2023
Conference call to be held today at 8:30 am ET
LOS ANGELES, Nov. 9, 2022 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:... More
